RUNX1 and neoplasm: In addition, RUNX1-IT1 overexpression can decrease the ALDH+ proportion of MHCC-97H cells, retard subcutaneous tumour formation derived from 1 × 103 HCC cells and participate in therapeutic resistance (P < 0.05, Supplementary Fig 1).